{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:44:06Z","timestamp":1793893446191,"version":"4.8.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Venetoclax (VEN), a small-molecule inhibitor of B cell leukemia\/lymphoma-2, is now FDA approved (November 2018) for use in acute myeloid leukemia (AML), specific to newly diagnosed elderly or unfit patients, in combination with a hypomethylating agent (HMA; including azacitidine or decitabine) or low-dose cytarabine. A recent phase-3 study compared VEN combined with either azacitidine or placebo, in the aforementioned study population; the complete remission (CR) and CR with incomplete count recovery (CRi) rates were 28.3% and 66.4%, respectively, and an improvement in overall survival was also demonstrated. VEN-based chemotherapy has also shown activity in relapsed\/refractory AML (CR\/CRi rates of 33\u201346%), high-risk myelodysplastic syndromes (CR 39% in treatment na\u00efve, 5\u201314% in HMA failure), and blast-phase myeloproliferative neoplasm (CR 25%); in all instances, an additional fraction of patients met less stringent criteria for overall response. Regardless, venetoclax-induced remissions were often short-lived (less than a year) but long enough to allow some patients transition to allogeneic stem cell transplant. Herein, we review the current literature on the use of VEN-based combination therapy in both acute and chronic myeloid malignancies and also provide an outline of procedures we follow at our institution for drug administration, monitoring of adverse events and dose adjustments.<\/jats:p>","DOI":"10.1038\/s41408-020-00388-x","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T08:12:03Z","timestamp":1606119123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"388_CR1","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.6093263","volume":"226","author":"Y Tsujimoto","year":"1984","unstructured":"Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C. & Croce, C. M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 226, 1097\u20131099 (1984).","journal-title":"Science."},{"key":"388_CR2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/335440a0","volume":"335","author":"DL Vaux","year":"1988","unstructured":"Vaux, D. L., Cory, S. & Adams, J. M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 335, 440\u2013442 (1988).","journal-title":"Nature."},{"key":"388_CR3","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/2159-8290.CD-17-0797","volume":"7","author":"JD Leverson","year":"2017","unstructured":"Leverson, J. D. et al. Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor Venetoclax. Cancer Discov. 7, 1376\u20131393 (2017).","journal-title":"Cancer Discov"},{"key":"388_CR4","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1038\/sj.leu.2401573","volume":"13","author":"M Andreeff","year":"1999","unstructured":"Andreeff, M. et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 13, 1881\u20131892 (1999).","journal-title":"Leukemia"},{"key":"388_CR5","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421\u20133428 (2008).","journal-title":"Cancer Res."},{"key":"388_CR6","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","volume":"14","author":"H Zhang","year":"2007","unstructured":"Zhang, H. et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 14, 943\u2013951 (2007).","journal-title":"Cell Death Differ."},{"key":"388_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","volume":"10","author":"M Konopleva","year":"2006","unstructured":"Konopleva, M. et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10, 375\u2013388 (2006).","journal-title":"Cancer Cell"},{"key":"388_CR8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan, R. et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 4, 362\u2013375 (2014).","journal-title":"Cancer Discov."},{"key":"388_CR9","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/leu.2014.72","volume":"28","author":"X Niu","year":"2014","unstructured":"Niu, X. et al. Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. Leukemia 28, 1557\u20131560 (2014).","journal-title":"Leukemia"},{"key":"388_CR10","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/leu.2014.44","volume":"28","author":"JM Bogenberger","year":"2014","unstructured":"Bogenberger, J. M. et al. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia 28, 1657\u20131665 (2014).","journal-title":"Leukemia"},{"key":"388_CR11","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","volume":"91","author":"T Tsao","year":"2012","unstructured":"Tsao, T. et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann. Hematol. 91, 1861\u20131870 (2012).","journal-title":"Ann. Hematol."},{"key":"388_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo, C. D. et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 19, 216\u2013228 (2018).","journal-title":"Lancet Oncol."},{"key":"388_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo, C. D. et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133, 7\u201317 (2019).","journal-title":"Blood"},{"key":"388_CR14","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","volume":"24","author":"DA Pollyea","year":"2018","unstructured":"Pollyea, D. A. et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat. Med. 24, 1859\u20131866 (2018).","journal-title":"Nat. Med."},{"key":"388_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J. Med."},{"key":"388_CR16","doi-asserted-by":"publisher","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","volume":"7","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 7, e724\u2013e736 (2020).","journal-title":"Lancet Haematol."},{"key":"388_CR17","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei, A. H. et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a Phase Ib\/II study. J. Clin. Oncol. 37, 1277\u20131284 (2019).","journal-title":"J. Clin. Oncol."},{"key":"388_CR18","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei, A. H. et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135, 2137\u20132145 (2020).","journal-title":"Blood"},{"key":"388_CR19","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","volume":"3","author":"AC Winters","year":"2019","unstructured":"Winters, A. C. et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 3, 2911\u20132919 (2019).","journal-title":"Blood Adv."},{"key":"388_CR20","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/ajh.25978","volume":"95","author":"E Morsia","year":"2020","unstructured":"Morsia, E. et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am. J. Hematol. 95, 1511\u20131521 (2020).","journal-title":"Am. J. Hematol."},{"key":"388_CR21","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/ajh.24780","volume":"92","author":"R Nanah","year":"2017","unstructured":"Nanah, R. et al. Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: single institution experience. Am. J. Hematol. 92, 866\u2013871 (2017).","journal-title":"Am. J. Hematol."},{"key":"388_CR22","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva, M. et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 6, 1106\u20131117 (2016).","journal-title":"Cancer Discov."},{"key":"388_CR23","doi-asserted-by":"publisher","first-page":"E202","DOI":"10.1002\/ajh.25146","volume":"93","author":"B Chyla","year":"2018","unstructured":"Chyla, B. et al. Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia. Am. J. Hematol. 93, E202\u2013E205 (2018).","journal-title":"Am. J. Hematol."},{"key":"388_CR24","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135, 791\u2013803 (2020).","journal-title":"Blood"},{"key":"388_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ajh.25000","volume":"93","author":"CD DiNardo","year":"2018","unstructured":"DiNardo, C. D. et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am. J. Hematol. 93, 401\u2013407 (2018).","journal-title":"Am. J. Hematol."},{"key":"388_CR26","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","volume":"103","author":"I Aldoss","year":"2018","unstructured":"Aldoss, I. et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Haematologica 103, e404\u2013e407 (2018).","journal-title":"Haematologica"},{"key":"388_CR27","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s00277-019-03719-6","volume":"98","author":"R Ram","year":"2019","unstructured":"Ram, R. et al. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study. Ann. Hematol. 98, 1927\u20131932 (2019).","journal-title":"Ann. Hematol."},{"key":"388_CR28","doi-asserted-by":"publisher","first-page":"106314","DOI":"10.1016\/j.leukres.2020.106314","volume":"90","author":"D Gaut","year":"2020","unstructured":"Gaut, D. et al. Venetoclax combination therapy in relapsed\/refractory acute myeloid leukemia: a single institution experience. Leuk. Res. 90, 106314 (2020).","journal-title":"Leuk. Res."},{"key":"388_CR29","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00277-020-03911-z","volume":"99","author":"YW Wang","year":"2020","unstructured":"Wang, Y. W. et al. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Ann. Hematol. 99, 501\u2013511 (2020).","journal-title":"Ann. Hematol."},{"key":"388_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/ejh.13218","volume":"102","author":"F Huemer","year":"2019","unstructured":"Huemer, F. et al. Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and\/or BIM. Eur. J. Haematol. 102, 437\u2013441 (2019).","journal-title":"Eur. J. Haematol."},{"key":"388_CR31","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1080\/10428194.2020.1761964","volume":"61","author":"C Ganzel","year":"2020","unstructured":"Ganzel, C. et al. Venetoclax is safe and efficacious in relapsed\/refractory AML. Leuk. Lymphoma 61, 2221\u20132225 (2020).","journal-title":"Leuk. Lymphoma"},{"key":"388_CR32","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/ajh.25859","volume":"85","author":"M Byrne","year":"2020","unstructured":"Byrne, M. et al. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. Am. J. Hematol. 85, 1006\u20131014 (2020).","journal-title":"Am. J. Hematol."},{"key":"388_CR33","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","volume":"3","author":"I Aldoss","year":"2019","unstructured":"Aldoss, I. et al. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Blood Adv. 3, 4043\u20134049 (2019).","journal-title":"Blood Adv."},{"key":"388_CR34","doi-asserted-by":"publisher","first-page":"E253","DOI":"10.1002\/ajh.25567","volume":"94","author":"I Aldoss","year":"2019","unstructured":"Aldoss, I. et al. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Am. J. Hematol. 94, E253\u2013E255 (2019).","journal-title":"Am. J. Hematol."},{"key":"388_CR35","doi-asserted-by":"publisher","unstructured":"Bewersdorf, J. P. et al. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. Haematologica 105, https:\/\/doi.org\/10.3324\/haematol.2019.242826 (2020).","DOI":"10.3324\/haematol.2019.242826"},{"key":"388_CR36","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1111\/bjh.16166","volume":"187","author":"I Aldoss","year":"2019","unstructured":"Aldoss, I. et al. Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia. Br. J. Haematol. 187, e45\u2013e48 (2019).","journal-title":"Br. J. Haematol."},{"key":"388_CR37","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1182\/blood-2019-124437","volume":"134","author":"AH Wei","year":"2019","unstructured":"Wei, A. H. et al. A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine in treatment-na\u00efve patients with higher-risk myelodysplastic syndrome. Blood 134, 568 (2019).","journal-title":"Blood"},{"key":"388_CR38","doi-asserted-by":"crossref","unstructured":"Garcia, J. S. et al. The prognostic impact of cytogenetic scors in patients with higher-risk myelodysplastic syndrome treated with venetoclax and azacitidine in a phase 1 study. EHA Abstr. 294712 (2020).","DOI":"10.1016\/S2152-2650(20)30969-1"},{"key":"388_CR39","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1182\/blood-2019-124994","volume":"134","author":"AM Zeidan","year":"2019","unstructured":"Zeidan, A. M. et al. A phase 1b study evaluating the safety and efficacy of venetoclax as monotherapy or in combination with azacitidine for the treatment of relapsed\/refractory myelodysplastic syndrome. Blood 134, 565 (2019).","journal-title":"Blood"},{"key":"388_CR40","unstructured":"Zeida, A. M. et al. A Phase 1B study evaluating the safety and efficacy of venetoclax combination with azacitidine for the treatment of relapsed\/refractory myelodysplastic syndrome. EHA Abstr. 295008 (2020)."},{"key":"388_CR41","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1182\/bloodadvances.2020001482","volume":"4","author":"BJ Ball","year":"2020","unstructured":"Ball, B. J. et al. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 4, 2866\u20132870 (2020).","journal-title":"Blood Adv."},{"key":"388_CR42","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1080\/10428194.2020.1775214","volume":"61","author":"A Azizi","year":"2020","unstructured":"Azizi, A. et al. Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leuk. Lymphoma 61, 2700\u20132707 (2020).","journal-title":"Leuk. Lymphoma"},{"key":"388_CR43","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1182\/blood-2019-126005","volume":"134","author":"J Cortes","year":"2019","unstructured":"Cortes, J. et al. Activity of venetoclax-based therapy in myelodysplastic syndrome (MDS). Blood 134, 1726 (2019).","journal-title":"Blood"},{"key":"388_CR44","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1182\/blood-2019-130158","volume":"134","author":"CN Harrison","year":"2019","unstructured":"Harrison, C. N. et al. Results from a phase 2 study of navitoclax in combination with ruxolitinib in patients with primary or secondary myelofibrosis. Blood 134, 671 (2019).","journal-title":"Blood"},{"key":"388_CR45","doi-asserted-by":"publisher","unstructured":"Gangat, N. et al. Venetoclax plus hypomethylating agent in blast phase myeloproliferative neoplasm: preliminary experience with 12 patients. Br. J. Haematol. https:\/\/doi.org\/10.1111\/bjh.17084 (2020) (In press).","DOI":"10.1111\/bjh.17084"},{"key":"388_CR46","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi, A. et al. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia 32, 1200\u20131210 (2018).","journal-title":"Leukemia"},{"key":"388_CR47","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","volume":"39","author":"SK Agarwal","year":"2017","unstructured":"Agarwal, S. K. et al. Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin. Ther. 39, 359\u2013367 (2017).","journal-title":"Clin. Ther."},{"key":"388_CR48","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz, R. A. et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J. Clin. Oncol. 36, 3043\u20133054 (2018).","journal-title":"J. Clin. Oncol."},{"key":"388_CR49","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s10147-016-0971-3","volume":"21","author":"K Tamura","year":"2016","unstructured":"Tamura, K. et al. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int. J. Clin. Oncol. 21, 996\u20131003 (2016).","journal-title":"Int. J. Clin. Oncol."},{"key":"388_CR50","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1345\/aph.1P296","volume":"44","author":"AN Vines","year":"2010","unstructured":"Vines, A. N., Shanholtz, C. B. & Thompson, J. L. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. Ann. Pharmacother. 44, 1529\u20131537 (2010).","journal-title":"Ann. Pharmacother."},{"key":"388_CR51","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424\u2013447 (2017).","journal-title":"Blood"},{"key":"388_CR52","doi-asserted-by":"publisher","unstructured":"Sandhu, K. S. et al. Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myeloid leukemia. Biol. Blood Marrow Transplant https:\/\/doi.org\/10.1016\/j.bbmt.2020.08.027 (2020) (In press).","DOI":"10.1016\/j.bbmt.2020.08.027"},{"key":"388_CR53","doi-asserted-by":"publisher","unstructured":"Herold, T. et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia https:\/\/doi.org\/10.1038\/s41375-020-0806-0 (2020).","DOI":"10.1038\/s41375-020-0806-0"},{"key":"388_CR54","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis, G. J. et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131, 1275\u20131291 (2018).","journal-title":"Blood"},{"key":"388_CR55","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1309\/AJCP5TSD3DZXFLCX","volume":"131","author":"A Al-Mawali","year":"2009","unstructured":"Al-Mawali, A., Gillis, D. & Lewis, I. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol 131, 16\u201326 (2009).","journal-title":"Am J Clin Pathol"},{"key":"388_CR56","doi-asserted-by":"publisher","first-page":"7500","DOI":"10.1200\/JCO.2020.38.15_suppl.7500","volume":"38","author":"CA Lachowiez","year":"2020","unstructured":"Lachowiez, C. A. et al. Phase Ib\/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +\/- azacitidine in IDH1-mutated hematologic malignancies. J. Clin. Oncol. 38, 7500 (2020).","journal-title":"J. Clin. Oncol."},{"key":"388_CR57","doi-asserted-by":"publisher","unstructured":"Mali, R. S. et al. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica https:\/\/doi.org\/10.3324\/haematol.2019.244020 (2020).","DOI":"10.3324\/haematol.2019.244020"},{"key":"388_CR58","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1182\/blood-2019-127416","volume":"134","author":"AE Perl","year":"2019","unstructured":"Perl, A. E. et al. Venetoclax in combination with gilteritinib in patients with relapsed\/refractory acute myeloid leukemia: a phase 1b study. Blood 134, 3910 (2019).","journal-title":"Blood"},{"key":"388_CR59","doi-asserted-by":"crossref","unstructured":"Joshi, M. et al. Salvage use of venetoclax-based therapy for relapsed AML post allogeneichematopoietic cell transplantation. BCJ (2020) (In press).","DOI":"10.1038\/s41408-021-00437-z"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00388-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T09:37:39Z","timestamp":1670233059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00388-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":59,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["388"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-00388-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"assertion":[{"value":"6 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"122"}}